Vinay Prasad describes his Vanderbilt colleagues as “despicable,” raising new questions about physicians’ conduct on social media

Weill Cancer Hub West secures $200M to support launch of UCSF-Stanford collaboration

A $100 million matching grant from the Weill Family Foundation is supporting the launch of the Weill Cancer Hub West—a collaboration between the UCSF Helen Diller Family Comprehensive Cancer Center and the Stanford Cancer Institute—set up to accelerate discoveries and speed the development of innovative new treatments for patients.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Drugs & Targets

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

FDA granted Breakthrough Therapy designation to elironrasib, a RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.

July 25, 2025

Vol.51 No.29

Funding Opportunities

Lung Cancer Research Foundation announces $3.75 million in research funding opportunities

The Lung Cancer Research Foundation announced funding opportunities to advance lung cancer research, including two new Team Science awards and an Early Career Investigator award.

July 18, 2025

Vol.51 No.28

Vinay Prasad describes his Vanderbilt colleagues as “despicable,” raising new questions about physicians’ conduct on social media

YOU MAY BE INTERESTED IN

Weill Cancer Hub West secures $200M to support launch of UCSF-Stanford collaboration

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

Lung Cancer Research Foundation announces $3.75 million in research funding opportunities

Renew today!

Subscriber content

Never miss an issue!

Login